

**M. Marengo**

**IMPLEMENTING SAFETY BARRIERS  
AND PREVENTING ACCIDENTAL  
EXPOSURE OF PATIENT AND STAFF**

*Medical Physicist  
University of Bologna*

[mario.marengo@unibo.it](mailto:mario.marengo@unibo.it)



# Accidents and incidents

A major concern of safety is preventing accidents / incidents in human activities.

Numerous definitions exist of accidents and incidents at work. The nature of the definitions often depends on the context and the purpose, such as accident prevention, compensation and statistics.

In the context of accident prevention, the phenomenon of accidents and incidents are often viewed in light of accident investigation and analysis. The main purpose is to gain insight in the (underlying) causes in order to prevent accidents in the future and to improve the safety.

An accident can be defined as an unplanned and uncontrolled event in which the action or reaction of an object, substance, person or radiation results in personal injury or the probability thereof.

*Heinrich, H., Industrial Accident Prevention, fourth edition, New York, 1959, first edition, 1931.*

*European Agency for Safety and Health at Work. <http://oshwiki.eu/wiki/>*

*Mahajan R.P., British Journal of Anaesthesia 105 (1): 69–75 (2010)*



# Incidents in Health Services in Italy

Accidents at work - Qualified professions in health and social services

	2015	2016	2017
N. of cases	6724	7260	7784
Death cases	3	3	3

N. of workers in the health services ca. 750000


N. of workers in social services ca. 350000

About 7 incidents/year every 1000 workers

Lethal incidents  $\sim 2.7\text{E-}06$  per year

## Incident in health services in Italy (2017)

*data from the INAIL data base*



## Distribuzione per Regione (2017)

Regione	Numero casi	%
Piemonte	1.008	12.9
Valle D'Aosta	40	0.5
Lombardia	1.139	14.6
Bolzano - Bozen	81	1
Trento	140	1.8
Veneto	981	12.6
Friuli Venezia Giulia	243	3.1
Liguria	411	5.3
Emilia Romagna	1.493	19.2
Toscana	790	10.1
Umbria	82	1.1
Marche	282	3.6
Lazio	233	3
Abruzzo	81	1
Molise	9	0.1
Campania	121	1.6
Puglia	191	2.5
Basilicata	31	0.4
Calabria	84	1.1
Sicilia	101	1.3
Sardegna	243	3.1
Totale complessivo	7.784	100

~ 86% of reports in North and Center Regions

# Prevention of accidents and incidents in NM

The BSS sets out requirements both for minimizing the likelihood of unintended and accidental medical exposures and for the ensuing investigation if such exposures occur.

*Excerpted from SSG-46 Par. 4.250:* A reduction in the probability of unintended or accidental medical exposures in Nuclear Medicine can be brought about by:

- (a) The introduction of “**safety barriers**” at identified critical points in the nuclear medicine pathway, with specific quality control checks at these points.
- (b) Encouraging a culture of always **working with awareness** and alertness.
- (c) Providing **detailed protocols and procedures** for each process.
- (d) Providing **sufficient** (educated and trained) **staff**, and an effective organization
- (e) **Continuous professional development** and practical/applications training of all staff
- (f) **Clear definitions of the roles**, responsibilities and functions of staff



# Specific to NM

Imaging in Nuclear Medicine is much different, compared to Radiology and other modalities.


The fact that radiopharmaceuticals are used as tracers of metabolic functions, means that what we are imaging is not “the organ” or “a system”, intended as their physical morphology, but rather the metabolism of the cells of the organ or the functionality of a system.

For these reasons, it is not directly expected that the “quality” of the images, expressed by descriptors like the spatial resolution, would be optimal; rather, the quantitative aspects of organs and system function are expected to be imaged with sufficient accuracy.

This explains also how and why the process of patient's imaging is of paramount importance, included patient's preparation, timing and eventual “provocative” actions, aimed to stimulate response of the organs / systems.

Thus, the optimization process should not be applied only the imaging procedure, but to the whole process ...

# QC, QA, QM



**Quality control:** is a part of quality assurance. The set of operations (programming, coordinating, implementing) intended to maintain or to improve quality. It covers monitoring, evaluation and maintenance at required levels of all characteristics of performance of equipment that can be defined, measured, and controlled.

**Quality Assurance:** all those planned and systematic actions necessary to provide adequate confidence that a structure, system, component or procedure will perform satisfactorily complying with agreed standards.


*From EU Directive 97/43*

**Quality Management:** That aspect of the overall management function that determines and implements the *quality policy*



# A comprehensive approach

- The IAEA has developed and introduced a comprehensive approach to Quality management in Nuclear Medicine
- This includes a checklist for assisting in the performance of audits (both internal and external)
- All the components of the process are checked (administration & management, human resources, radiation protection, equipment QA/QC, IT systems, clinical practice in diagnostic & therapeutic applications, radiopharmacy)
- Only a comprehensive approach can make possible a reliable process of optimization



# Accidents in Nuclear Medicine routine activity

## Safety of operators

Routine activity in Nuclear Medicine presents the possibility of some typical, and relatively frequent, accidents:

- Puncture with a syringe, during radiopharmaceutical preparation or following patient administration;
- Contamination in the management of body fluids
- Diffused “spray” contamination during injection;
- Irradiation in manipulation of sources (in particular therapeutic radiopharmaceuticals)
- Mechanical injury by heavy lead shielding components (e.g. lead bricks; leaded transport containers; hot cell's portals, etc.);
- ...

# Puncture

- During some steps in the preparation of radiopharmaceuticals, it is necessary to recap syringes. This operations should be made ONLY in a safe way, using appropriate tools. However, operators may avoid this, to “save time” or for an excess of confidence.
- After administration to patients, syringes SHOULD NEVER be recapped, and be disposed as they are in an appropriate sharps container. However, some times this aspect is not fully conceived as exposing the operator not only to the risk of radioactive contamination (relatively modest), but also to a significant risk of microbiological contamination.
- These accidents should be immediately noticed and reported. A procedure for centralized reporting of all punctures should be active in any Hospital, and should be used also for events regarding radioactive pharmaceuticals.
- In most part of the cases (excluding some radionuclides for therapeutic use), the microbiological risk is much more significant than radiation risk.
- The subject should be immediately referred for appropriate tests and profilaxis against major infective risks.
- Systematic use of gloves, reduces significantly all risks of contamination.

# Management of body fluids

- Procedures like White Blood Cells labelling and other, involve manipulation of blood samples.
- Urine bags, diapers and assistance to specific classes of patients present the risk of contamination.
- As in the case of puncture, these accidents should be immediately noticed and reported, according to the (existing) Hospital accident reporting procedure.
- In most part of the cases (excluding some radionuclides for therapeutic use), the microbiological risk is more significant than radiation risk.
- The subject should be immediately referred for appropriate tests and prophylaxis against major infective risks.
- Systematic use of gloves, reduces significantly all risks of contamination.

# Mechanical injury

- Even if referring to these risks may seem as not relevant, in a context mostly concerned with radiation protection, events such as crushing of the fingers with lead bricks or doors of hot cells, or crushing the toes due to drop of shielded transport containers, are relatively frequent.
- These events are not only painful, but can lead to permanent disability, and should be carefully prevented.
- It was reported at least one case of an operator killed by having the chest crushed by an hot cell, capsized during a shift.
- Preventive actions: all barriers should fixed and stable; periodical inspection.
- It essential focus the mind of workers to a general concept of safety, not considering ONLY radiation protection.



# Diffused radioactive contamination

- Even if infrequently, the needle of a syringe may get clogged during injection, producing a spray of radiopharmaceutical when the piston is pushed.
- The face, hairs and chest of the operator can be contaminated.
- Adopting proper injection procedure (e.g. using an i.v. line, aspirating blood prior to injecting etc.), these events can be avoided.
- In the case of such an event, care should be taken not to extend the contamination.
- Regular decontamination procedures should be followed.
- Monitoring of residual contamination should be performed by a MP / RPE.
- The accident should be reported, including an estimate of the effective dose to the skin.

# Accidents in Nuclear Medicine routine activity

## Safety of patients

Procedure	Incident / Accident
Request & scheduling	Wrong examination booked / Inappropriate examination booked / Repeated examination
Patient identification	Wrong patient injected
Patient preparation	Contraindications to proceed not observed / improper timing
QC of radiopharmaceuticals	Wrong radiopharmaceutical administered / Unexpected biodistribution
Traceability / identification of unit doses	Misadministration
Measurement of individual activity	Non correct activity injected / suboptimal imaging
Equipment QA and inspection	Poor image quality / Mechanical injury of patient



# Accidents in Nuclear Medicine routine activity

## Safety of patients

Errors that may contribute to incidents during the preparation of radiopharmaceuticals

Component	Possible errors
Storage of precursors, kits, cassettes etc.	Wrong environmental conditions may alter the products A product may have expired and not be taken out of use Poor demarcation of storage areas
Biological contamination during synthesis	A module or vial may not have been sealed adequately or aseptic conditions in a hot cell or laboratory may not be adequate, resulting in contamination of the product
Synthesis / labelling of the radiopharmaceutical	Inaccurate colour coding or labelling of kits Incorrect set-up of synthesis module, e.g. the module is not tightened or wrong loading of reagents / cassette
Quality control (QC)	Errors in laboratory procedures Inaccurate calibrations or equipment with poor sensitivity Components of the QC checks omitted
Dispensing of radiopharmaceutical	Poor procedures or environmental conditions that contaminate the product Inaccurate activity or mixing up of different products resulting from simultaneous dispensing of many vials in advance of the administration Missing, inaccurate, or ambiguous labels on vials, syringe, or protective shields
Receipt and control of vials of radiopharmaceutical	Poor system for checking orders to confirm the correct radiopharmaceutical and activity of each vial has been delivered

# Accidents in Nuclear Medicine routine activity

## Safety of patients

Factors that could contribute to an incident during patient preparation and administration

Component of the process	Possible errors
Patient preparation	Wrong instructions given to the patient Fasting condition not checked at time of examination Pregnancy or lactation not verified at time of exam. Biochemical tests omitted (e.g. glucose level )
Stress testing / pharmacological stimulation	Errors in the procedure. Errors in timing.
Patient identification	Identification not confirmed Lack of physical tools for identification (e.g. wristband) Poor management of patients with same name
Administration of radiopharmaceutical	Errors in the procedure Wrong radiopharmaceutical / activity administered Extravasation of injection Contraindications not checked

# Accidents in Nuclear Medicine routine activity

## Safety of patients

### Factors that could be neglected or set incorrectly during imaging

Component of the process	Possible errors
Gamma camera setup	Wrong collimator / energy window / imaging time / matrix size or other sampling parameters set. Inadequate QC for detection of faults (e.g. a photomultiplier not working).
PET scanner setup	Incorrect daily QC procedure (e.g. detector block is not working)
Multi-modality scans	Wrong or poorly optimized CT protocol selected
In all imaging modes	Wrong reconstruction algorithm chosen Balance between quality of the images, acquisition time, and administered activity sub-optimal
Scanner calibration	The scanner is not calibrated, or calibration has expired before imaging (e.g. sensitivity, standardized uptake value (SUV), centre of rotation, etc.)
Mechanical safety	Patient has not been secured to the imaging bed. Moving components of the scanner have not been checked. Tools, furniture or other objects lie in the trajectory of motion.



ACCEPTED MANUSCRIPT

# Guidance on prevention of unintended and accidental radiation exposures in nuclear medicine

C J Martin<sup>1</sup>, M Marengo<sup>2</sup>, J Vassileva<sup>3</sup>, F Giammarile<sup>3</sup>, G L Poli<sup>3</sup> and P Marks<sup>4</sup>

To cite this article before publication: Colin John Martin *et al* 2019 *J. Radiol. Prot.* in press <https://doi.org/10.1088/1361-6498/ab19d8>

# Radiation Safety and Accidental Radiation Exposures in Nuclear Medicine

Mario Marengo, PhD,<sup>\*</sup> Colin J Martin, PhD,<sup>†</sup> Sietske Rubow, PhD,<sup>‡</sup> Terez Sera, PhD,<sup>§</sup> Zayda Amador, PhD,<sup>||</sup> and Leonel Torres, PhD<sup>¶</sup>

Medical radiation accidents and unintended events may lead to accidental or unintended medical exposure of patients and exposure of staff or the public. Most unintended exposures in nuclear medicine will lead to a small increase in risk; nevertheless, these require investigation and a clinical and dosimetric assessment. Nuclear medicine staff are exposed to radiation emitted directly by radiopharmaceuticals and by patients after administration of radiopharmaceuticals. This is particularly relevant in PET, due to the penetrating 511 keV  $\gamma$ -rays. Dose constraints should be set for planning the exposure of individuals. Staff body doses of 1-25  $\mu$ Sv/GBq are reported for PET imaging, the largest component being from the injection. The preparation and administration of radiopharmaceuticals can lead to high doses to the hands, challenging dose limits for radionuclides such as  $^{90}\text{Y}$  and even  $^{18}\text{F}$ . The risks of contamination can be minimized by basic precautions, such as carrying out manipulations in purpose-built facilities, wearing protective clothing, especially gloves, and removing contaminated gloves or any skin contamination as quickly as possible. Airborne contamination is a potential problem when handling radioisotopes of iodine or administering radioaerosols. Manipulating radiopharmaceuticals in laminar air flow cabinets, and appropriate premises ventilation are necessary to improve safety levels. Ensuring patient safety and minimizing the risk of incidents require efficient overall quality management. Critical aspects include: the booking process, particularly if qualified medical supervision is not present; administration of radiopharmaceuticals to patients, with the risk of misadministration or extravasation; management of patients' data and images by information technology systems, considering the possibility of misalignment between patient personal data and clinical information. Prevention of possible mistakes in patient identification or in the management of patients with similar names requires particular attention. Appropriate management of pregnant or breast-feeding patients is another important aspect of radiation safety. In radiopharmacy activities, strict quality assurance should be implemented at all operational levels, in addition to adherence to national and international regulations and guidelines. This includes not only administrative aspects, like checking the request/prescription, patient's data and the details of the requested procedure, but also quantitative tests according to national/international pharmacopoeias, and measuring the dispensed activity with a calibrated activity meter prior to administration. In therapy with radionuclides, skin tissue reactions can occur following extravasation, which can result in localized doses of tens of Grays. Other relevant incidents include confusion of products for patients administered at the same time or malfunction of administration devices. Furthermore, errors in internal radiation dosimetry calculations for treatment planning may lead to under or over-treatment. According to literature, proper instructions are fundamental to keep effective dose to caregivers and family members after patient discharge below the Dose constraints. The IAEA Basic Safety Standards require measures to minimize the likelihood of

<sup>\*</sup>Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy.

<sup>†</sup>Department of Clinical Physics and Bioengineering, University of Glasgow, UK.

<sup>‡</sup>Nuclear Medicine Division, Stellenbosch University, Stellenbosch, South Africa.

<sup>§</sup>Department of Nuclear Medicine, University of Szeged, Szeged, Hungary.

<sup>||</sup>Radiation Protection Department, Centre of Isotopes, Havana, Cuba.

<sup>¶</sup>Nuclear Medicine Department, Centre of Isotopes, Havana, Cuba.

Address reprint requests to Mario Marengo, PhD, University of Bologna, Bologna, Italy. E-mail: [mario.marengo@unibo.it](mailto:mario.marengo@unibo.it)



# Misadministration

A misadministration happens when:

- A different radiopharmaceutical is administered instead of the intended one
- A different activity is given instead of the prescribed
- A unit dose prepared for Patient A is administered to Patient B, even if it is the correct radiopharmaceutical and activity (sentinel event)
- A wrong administration route is used

Even in the case of limited activity of a short lived NM radionuclide, a misadministration is considered a serious event, since the exposure of the patient in this case is completely **un-justified**.



# Patient's identification

As a difference compared to Radiology, in Nuclear Medicine the exposure of the patient happens at the time of the administration of the radiopharmaceutical, typically well in advance respect to the time of the examination.

An effective system for the correct identification of the patient prior to administration is therefore a fundamental requisite of patient's radiation protection (IAEA SRS no. 40, par. 5.3.1 and 5.3.2).

There are several methods to properly identify patients:

- Confirm the patient's name by asking at every step of the process; the question should be “Can you please tell me your name ?” and not “Are you Mr. John Wayne ?”
- Assign to every patient an identification number and cross-check the number at every step of the process.
- Assign to each patient a wristband or equivalent, with an identification bar code; colours of the wristband can help to identify specific groups of patients.



# Management of same name patients

A very specific problem of patient identification may arise with homonymous (same name) patients.

Several approaches are possible, and wristbands can be a substantial improvement.

However, in several centres, it is preferred to avoid booking same name patients in the same day; in these case a software rule is added in the RIS system, making impossible to add in the worklist a patient that has the same name as another already accepted. The new patient is booked the following day or ASAP.

Since NM examinations rarely are urgent, this is typically an accepted delay.



# Patient's identification & traceability

For proper **traceability**, it is suggested to adopt a specific paper module that follows the patient in every step of the process, and report on it all the passages, operations and the responsible operator e.g. :

- time of arrival;
- patient's response to specific questions;
- time of administration, exact activity administered, type of radiopharmaceutical and batch number (best made by sticking in the module a sticker that should come with every individual syringe)
- time of beginning of the imaging
- time of release from the Department

Different steps are under the responsibility of different operators (secretaries, nurses, technologists, physicians); a signature or code number of the operator in charge should be included.

## Software to support traceability

Pagina produzione		Modifica e stampa Produzione	
<div> <div> <div> <div> <div>Anno 2016</div> <div>Numero 405</div> </div> <div> <div>Data registrazione</div> <div>13/10/2016 08:10</div> </div> </div> <div> <div>Radiofarmaco</div> <div>18F-FDG</div> </div> </div> </div> <div> <div>Operatore</div> <div>CELLA T3</div> </div>			

Modello di sintesi

CELLA T3

N° Lotto

FDG2016/001256

Prodotti Dispositivi

Reagenti

Radionuclei

Fasi

Controlli in process

			Lotto prodotto	Quantità (g ML)
1	405	Cassette per FDG FAST/LAB	1322781	1.000000
2	260	Tancho assay 50 Tg	000594290	0.100000
3	405	Sampore Fastlab 10 (18F-FDG)	06A2016000061	3.200000
4				
5				
6				
7				
8				
9				
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				
21				
22				
23				
24				
25				
26				
27				
28				
29				
30				
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				
61				
62				
63				
64				
65				
66				
67				
68				
69				
70				
71				
72				
73				
74				
75				
76				
77				
78				
79				
80				
81				
82				
83				
84				
85				
86				
87				
88				
89				
90				
91				
92				
93				
94				
95				
96				
97				
98				
99				
100				

MODALITA':

Intesa

Procedi

Ricerca

ra Inizio Produzione

07:55

Ora fine

Preparazioni Radionuclidi da sintesi

Controlli di qualità

Data Produzione	Lotto	Descrizione POS	Preparato da	In corso	Pre-release	Post Release	Completati	Non Eseguiti
21/09/2016	DOT2016/001100	860a-DOTANOC	<a href="#">Visualizza</a>				<input type="checkbox"/>	<input type="checkbox"/>
21/09/2016	FDG2016/0001092	18F-FDG	<a href="#">Visualizza</a>				<input type="checkbox"/>	<input type="checkbox"/>
21/09/2016	COL2016/0001089	11C-COLINA	<a href="#">Visualizza</a>				<input type="checkbox"/>	<input type="checkbox"/>
20/09/2016	FDG2016/0001086	18F-FDG	<a href="#">Visualizza</a>				<input type="checkbox"/>	<input type="checkbox"/>
19/09/2016	SM2016/0001082	680a-PSMA	<a href="#">Visualizza</a>				<input type="checkbox"/>	<input type="checkbox"/>
19/09/2016	FDG2016/0001076	18F-FDG	<a href="#">Visualizza</a>				<input type="checkbox"/>	<input type="checkbox"/>
19/09/2016	COL2016/0001075	11C-COLINA	<a href="#">Visualizza</a>				<input type="checkbox"/>	<input type="checkbox"/>
16/09/2016	FDG2016/0001068	18F-FDG	<a href="#">Visualizza</a>				<input type="checkbox"/>	<input type="checkbox"/>
16/09/2016	FDG2016/0001060	18F-FDG	<a href="#">Visualizza</a>				<input type="checkbox"/>	<input type="checkbox"/>
16/09/2016	MET2016/0001058	11C-METIONINA	<a href="#">Visualizza</a>				<input type="checkbox"/>	<input type="checkbox"/>
15/09/2016	DOT2016/0001056	860a-DOTANOC	<a href="#">Visualizza</a>				<input type="checkbox"/>	<input type="checkbox"/>
15/09/2016	COL2016/0001054	11C-COLINA	<a href="#">Visualizza</a>				<input type="checkbox"/>	<input type="checkbox"/>

Data:

☐ Tutte le Preparazioni

Preparazioni Radionuclidi da Iniezione - Controlli di qualità						
Preparazione		18F-FDG				
Tipologia Analisi	Descrizione controllo	Frequenza	Esito	Note	Data controllo	
► Analisi Pre Release	(HPLC) PUREZZA CHIMICA (FDO)	1	conforme		21/09/2018 10:55	
Analisi Pre Release	(HPLC) PUREZZA CHIMICA (CICD)	1	conforme		21/09/2018 10:56	
Analisi Pre Release	(HPLC) IDENTITÀ RADIONUCLIDICA (RT 18F-FDG)	1	conforme		21/09/2018 10:56	
Analisi Pre Release	(HPLC)PERCENTUALE ATTIVITÀ 18F-FDG + 18F-FDM SU ATTIVITÀ TOTALE	98.7	conforme		21/09/2018 10:56	
Analisi Pre Release	(HPLC)PERCENTUALE ATTIVITÀ 18F-FDM SU ATTIVITÀ 18F-FDG + 18F-FDM	1.3	conforme		21/09/2018 10:56	
Analisi Pre Release	PUREZZA CHIMICA (RIFPORTO)	CONFORME L	conforme		21/09/2018 11:13	
Analisi Pre Release	(TLC) PERCENTUALE ATTIVITÀ 18F + 18F-PARZIALMENTE ACETILATI SU ATTIVITÀ TOTALE	3.6	conforme		21/09/2018 11:27	
Analisi Pre Release	(TLC) PERCENTUALE ATTIVITÀ 18F-FDG + 18F-FDM SU ATTIVITÀ TOTALE	98.4	conforme		21/09/2018 11:27	
Analisi Pre Release	pH	5.6	conforme		21/09/2018 11:32	
Analisi Pre Release	(SPETTROMETRIA GAMMA) IDENTITÀ RADIONUCLIDICA	conforme	conforme		21/09/2018 08:15	
► Analisi Pre Release	PUNTO DI BOLLA	subacqueato	conforme		21/09/2018 08:15	
Analisi Pre Release	CEP-01	CONFORME	conforme		21/09/2018 08:15	
Analisi Pre Release	(HPLC) SST: resolution FDMF DO	1.855	conforme		21/09/2018 09:04	
Analisi Pre Release	(HPLC) SST: Signal-to-Noise-Ratio (FDO)	1.656	conforme		21/09/2018 09:03	
Analisi Pre Release	(GC) SST: Signal-to-Noise-Ratio	CONFORME	conforme		21/09/2018 15:45	
Analisi Post Release	STERILITÀ (CFU)	1	conforme		22/09/2018 10:55	
Analisi Post Release	(SPETTROMETRIA GAMMA) PUREZZA RADIONUCLIDICA DOPO 24 ORE PERCENTUALE DEL	conforme	conforme		21/09/2018 10:52	
Analisi Post Release	(GAS CRONOMETRAG) G SOLVENTI RESIDUI (ACETONITRILE)	conforme	conforme		21/09/2018 10:52	

Esame	Cartella	Anamnesi	Chimica	Siringa	Somministrato	Ora esame	Cognome	Nome
PET con Colla						09:20	Scudato	Anna
PET con FDG						09:30	Scudato	Anna
PET NON FDG (ALTR)						09:45	Scudato	Anna
						09:50	Scudato	Anna
						10:00	Scudato	Anna
						10:05	Scudato	Anna
						10:05	Scudato	Anna
						10:35	Scudato	Anna
						10:45	Scudato	Anna

	Codice	Descrizione	Attività Mtq	Leugo	Coefficiente	Prepara	Ora pres.	Note	Volume	Nome utente	Cognome utente	Ora richiesta
	218F-FDG		388,376	PE1	30	IP	00:00			anna	anna	10:39



	Codice	Siringa	Radiofarmaco	Ora preparazione	Attività allestita Mtq	Utente	Ora Somm.	Attività Mtq somministrata	Nome Utente	Cognome utente
	218G177ES		18F-FDG	10:41	383,177		11:10	327,162		

- Specific softwares to support traceability are nowadays available
- Allow to trace all the process, from radionuclide production, to synthesis, QC and release of radiopharmaceuticals batches, patient's administration, image acquisition etc.

Malizia C et al, Eur J Nucl Med Mol Imaging (2016) 43 (Suppl 1):S666-S667



# Software to support traceability



- an additional benefit that traceability software bring, is in the ease of obtaining statistics, for example, data useful for assessing the Diagnostic Reference Levels

# Corrective actions following a misadministration

The correct identification of patients and radiopharmaceuticals, and the traceability of the process should ensure the substantial reduction of the risk of misadministration. However, in practice errors may happen.

It is the request that specific procedures exist, in order to be promptly applied in the undesired event of a misadministration; the procedures should include:

- Formal registration of the event
- Modality of communication of the event to the patient and the referring physician
- Any treatment that can be applied in order to reduce patient's absorbed dose
- Actuation of a Corrective Action, in order to identify the reasons for the deviation and adopt the necessary solutions in order to avoid a repetition
- Periodic review of all adverse events

*Example: a patient referred for bone scan, at the time of examination do not show proper biodistribution. Only limited renal activity was present. It was realized the patient was administered with DTPA instead that with MDP. The technologist in charge of preparing the radiopharmaceuticals was re-entering at work after a long maternal leave and has confused the vials. Corrective action was taken in order to grant a proper re-training and temporary coaching when staff re-enters after a long leave.*



# Extravasation of therapeutic radiopharmaceuticals

4 weeks p.i.



5 weeks p.i.

20 weeks p.i.

*Extravasation of yttrium 90–ibritumomab tiuxetan.*

*Siebeneck B., Clinical Journal of Oncology Nursing, (12) 2, 2008*

- Specific care should be adopted in administration of beta emitting and in particular of new alpha emitting radiopharmaceuticals

# Estimate of skin dose in the case of extravasation

**Varskin 4.0**

File Help

**Source Geometry**

☐ Point ☐ Sphere  
☐ Disk ☐ Slab  
☒ Cylinder

**Special Options**

☒ Include Photon Dose  
☐ Perform Volume Averaging

**Radionuclide Library**

Ba-137m  
Co-57  
Co-58  
Co-60  
Cs-137  
Ga-67  
I-131  
Mn-54  
Ra-223  
Sr-90  
Tc-99m  
**Y-90**

Activity Units  
MBq

Select  
Add  
Remove

☐ Use Distributed Source

**Selected Radionuclides**

**Y-90: 1.00E+00 MBq**

Edit Remove Clear

**Skin Averaging Area**

3.30E+01 cm<sup>2</sup>

**Exposure Time**

60 days

**Cylinder Source Irradiation Geometry**

Skin Thickness or Skin Density Thickness: 2.99E+00 mm

Air Gap Thickness 0 mm

Cover Thickness -3.00E+00 mm

Cover Density 0 g/cm<sup>2</sup>

Multiple Cover Calculator

Source Diameter 6.50E+00 cm

Source Thickness 3.00E+00 mm

Source Density 1 g/cm<sup>3</sup>

**vars skin 4.0**

Calculate Doses

**Non Volume Averaged Results**

Help

**Radionuclide: Activity**

**Y-90: 1.00E+00 MBq**

**All Radionuclides**

Unit Selection  
☐ English Units  
☒ SI Units

	Initial Dose Rate	Dose (No Decay)	Decay-Corrected Dose		Initial Dose Rate	Dose (No Decay)	Decay-Corrected Dose
Beta	3.22E+00 mGy/h	4.64E+03 mGy	3.02E+02 mGy	Beta	3.22E+00 mGy/h	4.64E+03 mGy	3.02E+02 mGy
Photon	0.00E+00 mGy/h	0.00E+00 mGy	0.00E+00 mGy	Photon	0.00E+00 mGy/h	0.00E+00 mGy	0.00E+00 mGy
Total	3.22E+00 mGy/h	4.64E+03 mGy	3.02E+02 mGy	Total	3.22E+00 mGy/h	4.64E+03 mGy	3.02E+02 mGy

Date/Time 12/02/2016 10:18:03 Source Geometry Cylinder Source

Source Diameter 6.50E+00 cm Source Thickness 3.00E+00 mm

Source Density 1.00E+00 g/cm<sup>3</sup>

Cover Thickness -3.00E+00 mm

Air Gap Thickness 0.00E+00 mm Irradiation Time 6.00E+01 days

Skin thickness 2.99E+00 mm Irradiation Area 3.30E+01 cm<sup>2</sup>

Print Results Close

# Be prepared

<p>SERVIZIO SANITARIO REGIONALE FASIS - FARMACIA ASL - ASL Policlinico E. D'Adda-Malpighi</p>	<p><b>ISTRUZIONE OPERATIVA AZIENDALE</b></p> <p><b>GESTIONE DEI CATETERI VENOSI PERIFERICI E DELLO STRAVASO NEL PAZIENTE ADULTO</b></p>	<p>IOA85</p> <p>Rev. 1</p> <p>Pag. 1/42</p>
---	---	---

## SOMMARIO

- 1.0 FINALITÀ
- 2.0 GRUPPO DI
- 3.0 DEFINIZIONI
- 4.0 GLOSSARIO
- 5.0 POSIZIONI
- 6.0 LAVAGGIO
- 7.0 CHIUSURA
- 8.0 SOSTITUZIONI
- 9.0 COMPLICAZIONI
- 10.0 PREVENZIONE
- 11.0 PREVENZIONE
- 12.0 PREVENZIONE
- 13.0 DOCUMENTAZIONE
- 14.0 ALLEGATI
- 15.0 MODULI

<p>SERVIZIO SANITARIO REGIONALE FASIS - FARMACIA ASL - ASL Policlinico E. D'Adda-Malpighi</p>	<p><b>ISTRUZIONE OPERATIVA AZIENDALE</b></p> <p><b>GESTIONE DEI CATETERI VENOSI PERIFERICI E DELLO STRAVASO NEL PAZIENTE ADULTO</b></p>	<p>IOA85</p> <p>Rev. 0</p> <p>Pag. 34/42</p>
---	---	--

## 11.0 PREVENZIONE E GESTIONE DEGLI STRAVASI DA RADIOFARMACI

### 11.1 CLASSIFICAZIONE DEI FARMACI

Come definito dal D.Leg. 24/04/2006 n. 219, si intende per radiofarmaco qualsiasi medicinale che, quando è pronto per l'uso, include uno o più radionuclidi (isotopi radioattivi) incorporati a scopo sanitario. I radiofarmaci sono impiegati sia a scopo diagnostico, sia per finalità terapeutiche.

Nella tabella 1 vengono elencati i principali radiofarmaci, classificati in base alla loro tossicità tissutale.

Le **sostanze irritanti** causano una reazione infiammatoria con dolore, bruciore, senso di oppressione e flebite, sito di inserzione e lungo la vena, che tende a risolversi velocemente in quanto sono sostanze rapidamente inattivate o velocemente metabolizzate.

Le **sostanze vescicanti/necrotizzanti** causano necrosi tissutale fino a perdita di spessore totale della cute e gravi danni alle strutture sottostanti in quanto, per il meccanismo d'azione, rimangono a lungo nel tessuto.

In linea generale, si ritiene di considerare **irritanti** i **radiofarmaci** per impiego **diagnostico** caratterizzati da breve tempo di dimezzamento fisico. I radiofarmaci per impiego **terapeutico** devono invece essere considerati **vescicanti/necrotizzanti**.




TABELLA 1: classificazione dei radio-farmaci irritanti, vescicanti/necrotizzanti

IRRITANTI	VESCICANTI / NECROTIZZANTI
<sup>99m</sup> Tc - Pertecnato	<sup>223</sup> Ra - Dicloruro (Xofigo)
<sup>99m</sup> Tc - MDP	<sup>90</sup> Y - Zevalin
<sup>99m</sup> Tc - MIBI	<sup>131</sup> I - NaI
<sup>99m</sup> Tc - MAG3	<sup>131</sup> I - MIBG
<sup>99m</sup> Tc - DMSA	Altri per farmaci impiegati per terapia
<sup>99m</sup> Tc - MAA	
<sup>99m</sup> Tc - Nanocoli	
<sup>18</sup> F - FDG	
<sup>18</sup> F - FLT	
<sup>18</sup> F - NaF	
<sup>18</sup> F - DOPA	
<sup>11</sup> C - Colina	
<sup>11</sup> C - Metionina	
<sup>68</sup> Ga - DOTANOC	
Altri per farmaci impiegati per la diagnostica	

<p>SERVIZIO SANITARIO REGIONALE FASIS - FARMACIA ASL - ASL Policlinico E. D'Adda-Malpighi</p>	<p><b>ISTRUZIONE OPERATIVA AZIENDALE</b></p> <p><b>GESTIONE DEI CATETERI VENOSI PERIFERICI E DELLO STRAVASO NEL PAZIENTE ADULTO</b></p>	<p>IOA85</p> <p>Rev. 0</p> <p>Pag. 36/42</p>
---	---	--

### 11.3 TRATTAMENTO



Rev. 1 Inseriti

STATO
Approvato
Approvato
Data di approvazione




# Patient fall / other mechanical injury

- Patient fall from the bed of scanners is the most frequent accident in diagnostic imaging Depts.
- This does not involve a dose absorption.
- ... It is the same !!!

Note that:

- The patient carrier bed and its accessories (mats, belts, other objects useful for immobilization) are components of the medical device
- They should be appropriately used
- Maintenance and periodical replacement are necessary





# Reporting of accidents / Incidents

Significant problems remain with local and national incident reporting systems. These include:

- Fear of punitive action
- Poor safety culture in an organization
- Lack of understanding among clinicians about what should be reported,
- Lack of awareness of how the reported incidents will be analysed,
- Lack of awareness on how will the reports lead to changes which will improve safety.

In the medical context, in particular, lack of systematic analysis of the reports and feedback directly to the clinicians and professionals is probably one the major barriers to engagement.

# Unified Incident Reporting form in Emilia Romagna

[illegible]

- Di questo modulo si può compilare a cura del responsabile -

<b>Stato dell'Evento</b>		
Contesto accidentale	Situazione pericolosa/Evento potenzialmente non coperto (ex persona malferma, S.T., con rischio surto di persona, ecc.)	Livello 1 <input type="checkbox"/>
	Situazione pericolosa/Evento potenzialmente sicuro ma identificato (es. preparazione di un farmaco sbagliato ma non somministrato, farmaco prescritto per un paziente allergico allo stesso ma non somministrato, apparecchi non presentati adeguatamente ma controllati prima della procedura, ecc.)	Livello 2 <input type="checkbox"/>
Eventi effettivi	<b>NESSUN ESITO</b> - evento si è risolto con nessun risultato sicuro (es. farmaco iniettato somministrato e non somministrato al paziente, inadeguata profilassi antibiotica senza conseguenze, ecc.)	Livello 3 <input type="checkbox"/>
	<b>ESITO MINORE</b> - conseguenze o malfunzionamenti minori controllati dal medico/responsabile sicuro o senza conseguenze rilevanti o trascurabili	Livello 4 <input type="checkbox"/>
	<b>ESITO MODERATO</b> - conseguenze o malfunzionamenti moderati senza conseguenze visibili del risultato, bisogno di cure mediche o infermieristiche, ecc./risultati minori (es. anemia da trasfusione, ecc.)	Livello 5 <input type="checkbox"/>
	<b>ESITO MIA MODERATO E CRISTALIZZO</b> - conseguenze o malfunzionamenti moderati senza conseguenze visibili del risultato/bisogno di cure mediche (es. procedure radiologiche, ecc.)/presenza di lesioni non maggiori (lesioni epiteliali, ustioni, ecc.)/conseguenze del trattamento	Livello 6 <input type="checkbox"/>
	<b>ESITO CRISTALIZZO</b> - conseguenze o malfunzionamenti di 1° o 2° grado (conseguenze visibili del risultato/bisogno di cure mediche) che danno origine alla diversità	Livello 7 <input type="checkbox"/>
	<b>ESITO SEVERO</b> - danno alla persona/lesione/lesione di diversa natura	Livello 8 <input type="checkbox"/>

<b>Valutazione dell'evento futuro</b>		
Possibilità di ricadimento di eventi analoghi	risposta (grazie al livello futuro)	SI <input type="checkbox"/> NO <input type="checkbox"/>
Possibilità solo di un evento analogo	risposta (grazie al livello futuro)	SI <input type="checkbox"/> NO <input type="checkbox"/>
L'evento ha determinato problemi di tipo organizzativo? (es. limiti, ecc.)	SI <input type="checkbox"/> NO <input type="checkbox"/>	SI <input type="checkbox"/> NO <input type="checkbox"/>
Quali?		
L'evento non ha causato problemi di tipo organizzativo?	SI <input type="checkbox"/> NO <input type="checkbox"/>	SI <input type="checkbox"/> NO <input type="checkbox"/>
Commentare		
Sono stati intrapresi adeguamenti a seguito dell'evento?		
Quali?		
L'evento ha determinato i costi, la durata delle degenze o il consumo di risorse?		
In che modo?		
Ci sono persone coinvolte da fare dell'evento?		
Se sì, quali azioni interventi sono necessari?		

Responsabile Medico dell'Incident Reporting	firma	Data
---	-------	------

1. La presente scheda vuole essere uno strumento per identificare i problemi e le cause ad essi connesse, che possono insorgere durante le attività di lavoro professionali. Per questo, in caso di altri obblighi derivanti da legge, è necessario effettuare con precedenza le segnalazioni alle autorità competenti.
2. La scheda può essere consegnata anche in forma anonima.
3. Dopo la compilazione della parte a cura del responsabile dell'Incident Reporting, viene in scheda in:



# International System SAFRON - Features




SAFRON reporting system:

- is non-punitive, anonymous, voluntary, educational and international system
- does not replace the regulatory reporting requirements of an institution
- collaborates with other reporting systems, and contains incident information gathered by the IAEA, ROSIS, CRCPD, ASN, Norway, Spain, and registered participants
- Currently has over 1500 events from 4 regulatory authorities and 102 facilities worldwide



*Credits to Debbie Gilley*



# Adding Radiopharmaceutical Therapy Events to SAFRON



IAEA

SAFRON

Safety Reporting and Learning System  
for Radiotherapy



Select Dataset: All incident reports ▼

Home

Process Steps

Incident Reports

Documents and Links

Registrations

Statistical Reports

Admin

Help

## Submit Incident Report

Provide incident report details.

Treatment modality:

External beam radiotherapy  
Brachytherapy

Equipment used:



Treatment method:



Date of discovery (YYYY-MM-DD):

Who discovered the incident?



How was the incident discovered?



(Add additional information in this incident)

SELECT

Required Fields

Credits to Debbie Gilley





# Adding Radiopharmaceutical Therapy Events to SAFRON



[Home](#) [Process Steps](#) [Incident Reports](#) [Documents and Links](#) [Registrations](#) [Statistical Reports](#) [Admin](#) [Help](#)

## Browse Process Steps

You can view all the process steps for a selected treatment modality.

Please choose your preferred dataset in the top right corner of this screen. Based on this selection, you can browse your own or all incident reports.

All process step  
for:

External beam radiotherapy  
Brachytherapy

- 1. Non-clinical phase
  - 1.1. Equipment and software specific activities
    - 1.1.1. New equipment
      - 1.1.1.1. Installation
      - 1.1.1.2. Acceptance tests
      - 1.1.1.3. Customization and configuration of equipment
      - 1.1.1.4. New equipment - Commissioning
      - 1.1.1.5. Data recording
      - 1.1.1.6. Preparation of data files for planning computers
      - 1.1.1.7. Other
    - 1.1.2. Routine machine QA
      - 1.1.2.1. Daily consistency checks
      - 1.1.2.2. Planned QA programme checks

Credits to Debbie Gilley



# Adding Radiopharmaceutical Therapy Events to SAFRON



What safety barrier	failed to identified the incident?	identified the incident?	might have identified it?
Verification of patient ID	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Verification that pretreatment condition have been taken into account	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Verification of imaging data for planning (CT scan, fusion, imaging modality, correct data set)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Verification reference points	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Physician peer review	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Review of treatment plan	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Independent confirmation of dose	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Time out	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Use of record and verifying system	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Verification of treatment accessories	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Image based position verification	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
In vivo dosimetry	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Intra-treatment monitoring	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Regular independent chart checks	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Regular clinic patient assessment	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Post treatment evaluations (evaluation of clinical and process)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Independent review of commissioning	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Regular internal audit	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Regular external audit	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Regular equipment performance verification	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other, please specify	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Credits to Debbie Gilley



# (Some) Conclusions

- Prevention of accidents, their management and reporting require not only appropriate provisional risk analysis, but also a properly organized Quality System, with detailed and cross-linked procedures, and a functional reporting system
- The whole process should be under strict control, starting from the mechanism of patient referral
- An accurate identification of the patient and of the unit doses to be administered is necessary; the concept of traceability should be applied
- The process should be developed and monitored in order to avoid mis-administrations; in the case such an event happens, there should be in place procedures aimed to proper communication and to limit the unjustified dose absorbed by the patient
- Each activity administered to patients should be individually measured and be conforming to international guidelines, the SPC of the radiopharmaceutical and the Diagnostic Reference Levels
- In the case of multi-modality imaging, the CT component should be properly tuned; if only non-diagnostic CT is required, for attenuation correction and navigation in the image set, limited current data can be used satisfactorily
- ...



## Tbd ...

Errors in medicine are common, and reporting them is a crucial component in their management and building the capacity to prevent them and being ready to react, in the undesirable occasion of an incident

Hospitals and health institutions should encourage the reporting of incidents and “near misses”, and investigate them promptly looking for causes. Various methods and platforms are available and many hospitals use software tools for online reporting, which facilitate efficient data collection. Despite these efforts, there is still resistance to reporting in some organizations.

A “no blame” environment should be created while balancing safety and accountability.

Learning from errors that do occur is a key factor in reducing the risk of repetition of similar mistakes, or at least decreasing their severity and maintaining and improving the quality of healthcare.

In addition to the internal reporting within the NM department, **a large scale gathering of experiences from events** is beneficial in looking for trends that extend beyond a facility and so helping to improve safety culture.

